[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605386":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":31,"studyPopulation":31,"armGroups":39,"interventions":51,"overallOfficials":31,"centralContacts":59,"locations":65,"responsibleParty":79,"collaborators":31,"id":83,"slug":31,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":31,"studyType":96,"phases":97,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":107,"whyStopped":31,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Neukidney Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Rate of change in creatinine glomerular filtration rate","compare the outcome effect of added QRX-3 drug to placebo in addition to standard therapy on the rate of change from baseline of creatinine GFR in ATN patients","28 days",[14,18],{"measure":15,"description":16,"timeFrame":17},"daily change in glomerular filtration rate in ml\u002Fmin","daily change in GFR by creatinine in mls\u002Fmin","7 days",{"measure":19,"description":20,"timeFrame":17},"daily change in cystatin C level in mg\u002Fdl","daily change in measured cystatin C level",[22],{"measure":23,"description":24,"timeFrame":25},"effect of QRX-3 on recovery of renal function in patients with ATN renal failure","comparism of number of patient achieving return to baseline renal function in both groups","28",{"allocation":27,"interventionModel":28,"interventionModelDescription":29,"primaryPurpose":30,"observationalModel":31,"timePerspective":31,"maskingInfo":32},"RANDOMIZED","PARALLEL","added QRX-3 to standard regime","TREATMENT",null,{"masking":33,"maskingDescription":31,"whoMasked":34},"QUADRUPLE",[35,36,37,38],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[40,46],{"label":41,"type":42,"description":43,"interventionNames":44},"Use of QRX-3 in addition to standard therapy","EXPERIMENTAL","QRX-3 drug orally as twice daily in addition to standard conventional therapy will be given to this group for 28 days",[45],"Drug: QRX-3",{"label":47,"type":48,"description":49,"interventionNames":50},"control group","PLACEBO_COMPARATOR","placebo twice daily will be given to this group in addition to standard therapy",[45],[52],{"type":53,"name":54,"description":55,"armGroupLabels":56,"otherNames":57},"DRUG","QRX-3","Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo",[41,47],[58],"Eseronate",[60],{"name":61,"role":62,"phone":63,"phoneExt":31,"email":64},"Ebima Okundaye, MD","CONTACT","9738855457","cliffordebima@gmail.com",[66],{"facility":67,"status":31,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":31},"Neukidney Inc","Rosharon","Texas","77583","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-95.46022,29.35218,{"lat":77,"lon":76},{"type":80,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Ebima Clifford Okundaye","President","100605386",false,"NCT07161843","Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)","Determine the Efficacy of Investigational Drug QRX-3 in Hospitalized Patients With Acute Tubular Necrosis Pattern of Acute Renal Failure","QRX3 in ARF","Inclusion Criteria:\n\n* Hospitalized patients\n* presence of Acute renal failure\n* Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of \\>2%\n* willingness to participate\n\nExclusion Criteria:\n\nHigh risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status","ALL","10 Years","80 Years",{"count":94,"type":95},500,"ESTIMATED","INTERVENTIONAL",[98,99],"PHASE2","PHASE3","Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure",[102,103],"Acute Renal Failure (ARF)","Acute Tubular Necrosis",[105,106],"acute renal failure","acute tubular necrosis","NOT_YET_RECRUITING","2026-02-12",{"date":110,"type":111},"2026-02-18","ACTUAL",{"date":113,"type":95},"2026-06-30",{"date":115,"type":95},"2027-02-01",{"name":81,"class":6},1]